Drug profile · INN
hepatitis b vaccine (recombinant dna)
HBVAXPRO
hepatitis b vaccine (recombinant dna) (HBVAXPRO) is a surface antigen (hbsag) vaccine antigen.
EMA: approved Antiinfectives for systemic use (J07) J07BC01
Patents linked 0
Pipeline programs 1
News articles 0
Drug details — hepatitis b vaccine (recombinant dna)
- Class
- Antiinfectives for systemic use (J07)
- Route
- —
- Patents
- 0
- Programs
- 1
- Data quality
- 0.83
Quick answer
hepatitis b vaccine (recombinant dna) (HBVAXPRO) is a surface antigen (hbsag) vaccine antigen.
Key facts
INN hepatitis b vaccine (recombinant dna)
Brand HBVAXPRO
Mechanism Surface antigen (HBsAg) vaccine antigen
Target Surface antigen (HBsAg)
Therapeutic class Antiinfectives for systemic use (J07)
ATC code J07BC01
Mechanism of action
Surface antigen (HBsAg) vaccine antigen
Primary target: Surface antigen (HBsAg)
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is hepatitis b vaccine (recombinant dna)?
hepatitis b vaccine (recombinant dna) (HBVAXPRO) is a surface antigen (hbsag) vaccine antigen.
What is the brand name for hepatitis b vaccine (recombinant dna)?
HBVAXPRO is a marketed brand name for hepatitis b vaccine (recombinant dna). Check FDA Drugs@FDA for the current US label holder and prescribing information.